Overcoming Challenges to Sustaining LDL-C Reduction in ASCVD

The panelists discuss the real-world barriers that make it difficult for patients with ASCVD to maintain sustained LDL-C reduction over time. Despite strong evidence linking lower LDL-C levels with improved outcomes, the experts note that treatment inertia, poor adherence, and cost barriers often prevent patients from achieving long-term control. Many patients discontinue therapy when they feel better after a cardiac event, not realizing that lipid-lowering must be continued indefinitely. The panelists also point to fragmented care—with transitions from hospital to outpatient settings—where therapy intensification opportunities are frequently missed. Even when non-statin agents are prescribed, access challenges and prior authorizations limit their consistent use. The experts emphasize the importance of clear patient education, simplified regimens, and team-based follow-up to reinforce adherence. They agree that improving continuity of care and addressing system-level obstacles are essential to achieving durable LDL-C reduction and preventing recurrent cardiovascular events.